Marcum MicroCap Conference
June 15-16, 2017
Grand Hyatt Hotel, New York, NY
The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with fund managers and high net worth individuals interested in small-cap equities. The two-day 2017 conference will include feature presentations by CEOs and CFOs from several principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Keynote speakers at this year's event are James Carville, Mary Matalin and Lawrence Kudlow. For more information on the conference, visit www.marcummicrocap.com
Presenting Companies
| 9:30am | ||
| 10am | ||
| 10:30am | ||
| 11am | ||
| 11:30am | ||
| 12pm |
9am
AEterna Zentaris (AEZS)
AEterna Zentaris (NASDAQ: AEZS) is a specialty biopharmaceutical company engaged in developing and commercializing novel pharmaceutical therapies. The company recently completed phase 3 studies of two internally developed compounds and intends to license out certain commercial rights of internally developed products to licensees in non-U.S. territories where such out-licensing would enable the company to ensure development, registration and launch of its product candidates. For more information, visit the company's website at www.aezsinc.com www.aezsinc.com
Mateon Therapeutics (MATN)
Mateon Therapeutics (OTC: MATN) is a biopharmaceutical company focused on vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents(AAs), which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action. The company believes it can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to central tumor cell death while AAs prevent formation of new tumor blood vessels. For more information, visit the company's website at www.mateon.com
10am
NeuroMetrix (NURO)
NeuroMetrix (NASDAQ: NURO) is a commercial stage, innovation driven healthcare company combining bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy. For more information, visit the company's website at www.neurometrix.com
Orgenesis (ORGS)
Orgenesis (OTC: ORGS) is a biopharmaceutical company with unique expertise and experience in cell therapy development and manufacturing. The company's MaSTherCell subsidiary is able to deliver optimized process industrialization capacities to cell therapy companies. MaSTherCell's customers include many of the world's leading pharmaceutical and biotech companies. Orgenesis is a pioneer in the process of trans-differentiation (cell reprograming), whereby an adult cell is converted into another type of cell. Orgenesis has successfully reprogramed human liver cells into glucose-responsive, fully functional, insulin producing cells. For more information, visit the company's website at www.orgenesis.com
RespireRx Pharmaceuticals (RSPI)
RespireRx Pharmaceuticals (OTC: RSPI) is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. The company's current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress. The company owns patents and patent applications, and holds exclusive licenses, for certain families of chemical compounds that claim the chemical structures and their use in the treatment of these and other disorders. For more information, visit the company's website at www.respirerx.com
VolitionRX (VNRX)
VolitionRX (NYSE: VNRX) is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present. The company's products aim to help to diagnose a range of cancers quickly, simply, accurately and cost effectively since early diagnosis often has the potential to prolong the life of patients. For more information, visit the company's website at www.volitionrx.com
MagneGas (MNGA)
MagneGas (NASDAQ: MNGA) owns a patented process that converts various renewables and liquid wastes into MagneGas fuels. These fuels can be used as an alternative to natural gas or for metal cutting. The company's testing has shown that its metal cutting fuel "MagneGas2®" is faster, cleaner and more productive than other alternatives on the market. It is also cost effective and safe to use with little changeover costs. The company currently sells MagneGas2® into the metal working market as a replacement to acetylene. For more information, visit the company's website at www.magnegas.com
10:30am
ENDRA Life Sciences (NDRAU)
ENDRA Life Sciences (NASDAQ: NDRAU) develops photo-and thermo-acoustic medical technologies bringing new capabilities to existing ultrasound systems. ENDRA's photo-acoustic solutions help medical researchers screen and modify disease models with high image quality and volume scanning speed. ENDRA has a global installed base of leading institutions using its Nexus-128 system, the only commercially available 3D imaging system for imaging anatomy, physiology and labeled molecular targets. ENDRA's thermo-acoustic technology is being developed for use with existing ultrasound equipment to visualize tissue function, composition, and monitor a variety of therapeutic interventions. For more information, visit the company's website at www.endrainc.com
InspireMD (NSPR)
InspireMD (NYSE: NSPR) was founded in 2005 with the purpose of creating a technology that could solve the problem of embolization in high risk vascular procedures. The company has grown to include a portfolio of embolic protection systems, which it both manufactures and commercializes. Today, InspireMD is a global company headquartered in Boston, MA. InspireMD seeks to utilize its proprietary MicroNetTM technology to make its products the industry standard for embolic protection by providing a superior solution to the key clinical issues of vascular procedures. For more information, visit the company's website at inspiremd.com
Roka Bioscience (ROKA)
Roka Bioscience (NASDAQ: ROKA) is dedicated to developing rapid, highly accurate molecular assays and instrument systems for the food safety industry. The company's Atlas® System represents a new tier of molecular rapid pathogen testing, offering automation and technology that brings true walk-away convenience and workflow advantages to the laboratory. Roka is focused on creating novel testing solutions that help manufacturers mitigate risks, protect their brands, and meet the increasing testing demands now and for years to come. For more information, visit the company's website at rokabio.com
11am
Bionik Laboratories (BNKL)
Bionik Laboratories (OTC: BNKL) is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development. For more information, visit the company's website at www.bioniklabs.com
Eco Building Products (ECOB)
Eco Building Products (OTC: ECOB) is a manufacturer of proprietary, environmentally conscientious chemistry utilizing patent pending ECOB WoodSurfaceFilm™ and FRC™ technology (Fire Retardant Coating). Eco's products protect against fire, mold/mycotoxins, fungal-decay, wood ingesting insects and termites. Eco is headquartered in San Diego, CA and goes to market through licensed affiliates nationwide. For more information, visit the company's website at www.ecob.net
GEE Group (JOB)
GEE Group (NYSE: JOB) is a provider of specialized staffing solutions and is the successor to employment offices doing business since 1893. The company operates in two industry segments, providing professional staffing services and solutions in the information technology, engineering, finance and accounting specialties and commercial staffing services. In the healthcare sector, GEE Group, through its Scribe Solutions brand, staffs medical scribes. Additionally, the company provides contract and direct hire professional staffing services. For more information, visit the company's website at www.geegroup.com
MYnd Analytics (MYAN)
MYnd Analytics (OTC: MYAN) is a predictive analytics company that has developed a cloud based support tool to help physicians reduce trial and error treatment in mental health. The company provides objective clinical decision support to mental healthcare providers for the personalized treatment of multiple behavioral disorders. The company uses its neurometric platform to generate Psychiatric Electroencephalogram Evaluation Registry (PEER) Reports to predict the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders. For more information, visit the company's website at www.myndanalytics.com
Pressure Biosciences (PBIO)
Pressure Biosciences (OTC: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. The company's products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Over 250 PCT systems are installed worldwide and over 100 publications cite the advantages of the PCT platform over competitive methods. For more information, visit the company's website at www.pressurebiosciences.com
11:30am
Digital Power (DPW)
Digital Power (NYSE: DPW) designs, manufactures and sells high-grade customized and off-the-shelf power system solutions. The company's products are used in demanding telecom, industrial, medical and military applications where customers demand high density, high efficiency and ruggedized power solutions. The company's wholly owned subsidiary, Digital Power Limited branded as Gresham Power Electronics, is based in Salisbury, UK. Digital Power's is headquartered in Fremont, California. For more information, visit the company's website at www.digipwr.com
Yield10 Bioscience (YTEN)
Yield10 Bioscience (NASDAQ: YTEN) is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 is leveraging an extensive track record of innovation based around optimizing the flow of carbon in living systems. By working on new approaches to improve fundamental elements of plant photosynthetic efficiency and optimizing seed production, Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean, and corn. Yield10 is based in Woburn, MA. For more information about the company, please visit www.yield10bio.com
12pm
Tonix Pharmaceuticals (TNXP)
Tonix Pharmaceuticals (NASDAQ: TNXP) is developing innovative pharmaceutical products to address major public health challenges. In addition to TNX-102 SL for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, as a potential smallpox-preventing vaccine. Company executives have a track record of success in drug development, regulatory approvals, and product launch activities. For more information, visit the company's website at www.tonixpharma.com
